"Botrule Rrule\\\" valign=\\\"top\\\">19</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Musculoskeletal and Connective Tissue Disorders</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Arthralgia</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">15</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Nervous System Disorders</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Headache</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">20</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Dysgeusia</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">12</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Dizziness</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">11</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Skin and Subcutaneous Tissue Disorders</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Alopecia</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">12</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Investigations</span></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Weight decreased</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">14</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td></tr></tbody></table><a name=\\\"t15\\\"></a><table width=\\\"100%\\\"><caption><span>Table 15: Laboratory Abnormalities for Patients Receiving VERZENIO in MONARCH 1</span></caption><col align=\\\"left\\\" width=\\\"28.800%\\\"/><col align=\\\"left\\\" width=\\\"25.950%\\\"/><col align=\\\"left\\\" width=\\\"22.625%\\\"/><col align=\\\"left\\\" width=\\\"22.625%\\\"/><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"middle\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"3\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">VERZENIO</span><br/><span class=\\\"Bold\\\">N=132</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">All Grades</span><br/><span class=\\\"Bold\\\">%</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Grade 3</span><br/><span class=\\\"Bold\\\">%</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Grade 4</span><br/><span class=\\\"Bold\\\">%</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Creatinine increased</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">99</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">White blood cell decreased</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">91</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">28</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Neutrophil count decreased</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">88</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">22</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">4.6</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Anemia</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">69</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Lymphocyte count decreased</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">42</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">13</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0.8</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Platelet count decreased</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">41</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">2.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">ALT increased</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">31</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">3.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">AST increased</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">30</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">3.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td></tr></tbody></table></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s36\\\"></a><a name=\\\"section-6.1.2.3.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Creatinine Increased</span></p><p>Abemaciclib has been shown to increase serum creatinine due to inhibition of renal tubular secretion transporters, without affecting glomerular function <span class=\\\"Italics\\\">[see Clinical Pharmacology (<a href=\\\"#s67\\\">12.3</a>)]</span>. In clinical studies, increases in serum creatinine (mean increase, 0.2-0.3 mg/dL) occurred within the first 28-day cycle of VERZENIO dosing, remained elevated but stable through the treatment period, and were reversible upon treatment discontinuation. Alternative markers such as BUN, cystatin C, or calculated GFR, which are not based on creatinine, may be considered to determine whether renal function is impaired.</p></div></div></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"90375-7\\\"><a name=\\\"s37\\\"></a><a name=\\\"section-6.2\\\"></a><p></p><h2>6.2 Postmarketing Experience</h2><p class=\\\"First\\\">The following adverse reactions have been identified during post-approval use of VERZENIO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p><span class=\\\"Italics\\\">Respiratory disorders</span>: Interstitial lung disease (ILD)/pneumonitis <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s18\\\">5.3</a>)]</span>.</p></div></section>\",\n            \"drugInteractions\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34073-7\\\"><a name=\\\"s38\\\"></a><a name=\\\"section-7\\\"></a><p></p><h1>7 DRUG INTERACTIONS</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s39\\\"></a><a name=\\\"section-7.1\\\"></a><p></p><h2>7.1 Effect of Other Drugs on VERZENIO</h2><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s40\\\"></a><a name=\\\"section-7.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">CYP3A Inhibitors</span></p><p>Strong and moderate CYP3A4 inhibitors increased the exposure of abemaciclib plus its active metabolites to a clinically meaningful extent and may lead to increased toxicity.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s41\\\"></a><a name=\\\"section-7.1.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Ketoconazole</span></p><p>Avoid concomitant use of ketoconazole. Ketoconazole is predicted to increase the AUC of abemaciclib by up to 16-fold <span class=\\\"Italics\\\">[see Clinical Pharmacology (<a href=\\\"#s67\\\">12.3</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s42\\\"></a><a name=\\\"section-7.1.1.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Other Strong CYP3A Inhibitors</span></p><p>In patients with recommended starting doses of 200 mg twice daily or 150 mg twice daily, reduce the VERZENIO dose to 100 mg twice daily with concomitant use of strong CYP3A inhibitors other than ketoconazole. In patients who have had a dose reduction to 100 mg twice daily due to adverse reactions, further reduce the VERZENIO dose to 50 mg twice daily with concomitant use of strong CYP3A inhibitors. If a patient taking VERZENIO discontinues a strong CYP3A inhibitor, increase the VERZENIO dose (after 3-5 half-lives of the inhibitor) to the dose that was used before starting the inhibitor. Patients should avoid grapefruit products <span class=\\\"Italics\\\">[see</span><span class=\\\"Italics\\\">Dosage and Administration (<a href=\\\"#s9\\\">2.2</a>) and Clinical Pharmacology (<a href=\\\"#s67\\\">12.3</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s43\\\"></a><a name=\\\"section-7.1.1.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Moderate CYP3A Inhibitors</span></p><p>With concomitant use of moderate CYP3A inhibitors, monitor for adverse reactions and consider reducing the VERZENIO dose in 50 mg decrements as demonstrated in <a href=\\\"#t1\\\">Table 1</a>, if necessary.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s44\\\"></a><a name=\\\"section-7.1.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Strong and Moderate CYP3A Inducers</span></p><p>Coadministration of strong or moderate CYP3A inducers decreased the plasma concentrations of abemaciclib plus its active metabolites and may lead to reduced activity. Avoid concomitant use of strong or moderate CYP3A inducers and consider alternative agents <span class=\\\"Italics\\\">[see Clinical Pharmacology (<a href=\\\"#s67\\\">12.3</a>)]</span>.</p></div></div></section>\",\n            \"clinicalPharmacology\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34090-1\\\"><a name=\\\"s63\\\"></a><a name=\\\"section-10\\\"></a><p></p><h1>12 CLINICAL PHARMACOLOGY</h1><div class=\\\"Section\\\" data-sectioncode=\\\"43679-0\\\"><a name=\\\"s64\\\"></a><a name=\\\"section-10.1\\\"></a><p></p><h2>12.1 Mechanism of Action</h2><p class=\\\"First\\\">Abemaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). These kinases are activated upon binding to D-cyclins. In estrogen receptor-positive (ER+) breast cancer cell lines, cyclin D1 and CDK4/6 promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation. In vitro, continuous exposure to abemaciclib inhibited Rb phosphorylation and blocked progression from G1 into S phase of the cell cycle, resulting in senescence and apoptosis. In breast cancer xenograft models, abemaciclib dosed daily without interruption as a single agent or in combination with antiestrogens resulted in reduction of tumor size.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"43681-6\\\"><a name=\\\"s65\\\"></a><a name=\\\"section-10.2\\\"></a><p></p><h2>12.2 Pharmacodynamics</h2><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s66\\\"></a><a name=\\\"section-10.2.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Cardiac Electrophysiology</span></p><p>Based on evaluation of the QTc interval in patients and in a healthy volunteer study, abemaciclib did not cause large mean increases (i.e., 20 ms) in the QTc interval.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"43682-4\\\"><a name=\\\"s67\\\"></a><a name=\\\"section-10.3\\\"></a><p></p><h2>12.3 Pharmacokinetics</h2><p class=\\\"First\\\">The pharmacokinetics of abemaciclib were characterized in patients with solid tumors, including breast cancer, and in healthy subjects.</p><p>Following single and repeated twice daily dosing of 50 mg (0.3 times the approved recommended 150 mg dosage) to 200 mg of abemaciclib, the increase in plasma exposure (AUC) and C<span class=\\\"Sub\\\">max</span> was approximately dose proportional. Steady state was achieved within 5 days following repeated twice daily dosing, and the estimated geometric mean accumulation ratio was 2.3 (50% CV) and 3.2 (59% CV) based on C<span class=\\\"Sub\\\">max</span> and AUC, respectively.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s68\\\"></a><a name=\\\"section-10.3.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Absorption</span></p><p>The absolute bioavailability of abemaciclib after a single oral dose of 200 mg is 45% (19% CV). The median T<span class=\\\"Sub\\\">max</span> of abemaciclib is 8.0 hours (range: 4.1-24.0 hours).</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s69\\\"></a><a name=\\\"section-10.3.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Effect of Food</span></p><p>A high-fat, high-calorie meal (approximately 800 to 1000 calories with 150 calories from protein, 250 calories from carbohydrate, and 500 to 600 calories from fat) administered to healthy subjects increased the AUC of abemaciclib plus its active metabolites by 9% and increased C<span class=\\\"Sub\\\">max</span> by 26%.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s70\\\"></a><a name=\\\"section-10.3.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Distribution</span></p><p>In vitro, abemaciclib was bound to human plasma proteins, serum albumin, and alpha-1-acid glycoprotein in a concentration independent manner from 152 ng/mL to 5066 ng/mL. In a clinical study, the mean (standard deviation, SD) bound fraction was 96.3% (1.1) for abemaciclib, 93.4% (1.3) for M2, 96.8% (0.8) for M18, and 97.8% (0.6) for M20. The geometric mean systemic volume of distribution is approximately 690.3 L (49% CV).</p><p>In patients with advanced cancer, including breast cancer, concentrations of abemaciclib and its active metabolites M2 and M20 in cerebrospinal fluid are comparable to unbound plasma concentrations.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s71\\\"></a><a name=\\\"section-10.3.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Elimination</span></p><p>The geometric mean hepatic clearance (CL) of abemaciclib in patients was 26.0 L/h (51% CV), and the mean plasma elimination half-life for abemaciclib in patients was 18.3 hours (72% CV).</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s72\\\"></a><a name=\\\"section-10.3.3.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Metabolism</span></p><p>Hepatic metabolism is the main route of clearance for abemaciclib. Abemaciclib is metabolized to several metabolites primarily by cytochrome P450 (CYP) 3A4, with formation of N-desethylabemaciclib (M2) representing the major metabolism pathway. Additional metabolites include hydroxyabemaciclib (M20), hydroxy-N-desethylabemaciclib (M18), and an oxidative metabolite (M1). M2, M18, and M20 are equipotent to abemaciclib and their AUCs accounted for 25%, 13%, and 26% of the total circulating analytes in plasma, respectively.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s73\\\"></a><a name=\\\"section-10.3.3.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Excretion</span></p><p>After a single 150 mg oral dose of radiolabeled abemaciclib, approximately 81% of the dose was recovered in feces and approximately 3% recovered in urine. The majority of the dose eliminated in feces was metabolites.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s74\\\"></a><a name=\\\"section-10.3.4\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Specific Populations</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s75\\\"></a><a name=\\\"section-10.3.4.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Age, Gender, and Body Weight</span></p><p>Based on a population pharmacokinetic analysis in patients with cancer, age (range 24-91 years), gender (134 males and 856 females), and body weight (range 36-175 kg) had no effect on the exposure of abemaciclib.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s76\\\"></a><a name=\\\"section-10.3.4.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Patients with Renal Impairment</span></p><p>In a population pharmacokinetic analysis of 990 individuals, in which 381 individuals had mild renal impairment (60 mL/min ≤ CLcr &lt;90 mL/min) and 126 individuals had moderate renal impairment (30 mL/min ≤ CLcr &lt;60 mL/min), mild and moderate renal impairment had no effect on the exposure of abemaciclib <span class=\\\"Italics\\\">[see Use in Specific Populations (<a href=\\\"#s60\\\">8.6</a>)]</span>. The effect of severe renal impairment (CLcr &lt;30 mL/min) on pharmacokinetics of abemaciclib is unknown.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s77\\\"></a><a name=\\\"section-10.3.4.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Patients with Hepatic Impairment</span></p><p>Following a single 200 mg oral dose of abemaciclib, the relative potency adjusted unbound AUC<span class=\\\"Sub\\\">0-INF</span> of abemaciclib plus its active metabolites (M2, M18, M20) in plasma increased 1.2-fold in subjects with mild hepatic impairment (Child-Pugh A, n=9), 1.1-fold in subjects with moderate hepatic impairment (Child-Pugh B, n=10), and 2.4-fold in subjects with severe hepatic impairment (Child-Pugh C, n=6) relative to subjects with normal hepatic function (n=10) <span class=\\\"Italics\\\">[see Use in Specific Populations (<a href=\\\"#s61\\\">8.7</a>)]</span>. In subjects with severe hepatic impairment, the mean plasma elimination half-life of abemaciclib increased to 55 hours compared to 24 hours in subjects with normal hepatic function.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s78\\\"></a><a name=\\\"section-10.3.5\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Drug Interaction Studies</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s79\\\"></a><a name=\\\"section-10.3.5.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Effects of Other Drugs on Abemaciclib</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s80\\\"></a><a name=\\\"section-10.3.5.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Strong CYP3A Inhibitors:</span> Ketoconazole (a strong CYP3A inhibitor) is predicted to increase the AUC of abemaciclib by up to 16-fold.</p><p>Coadministration of 500 mg twice daily doses of clarithromycin (a strong CYP3A inhibitor) with a single 50 mg dose of VERZENIO (0.3 times the approved recommended 150 mg dosage) increased the relative potency adjusted unbound AUC<span class=\\\"Sub\\\">0-INF</span> of abemaciclib plus its active metabolites (M2, M18, and M20) by 2.5-fold relative to abemaciclib alone in cancer patients.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s81\\\"></a><a name=\\\"section-10.3.5.1.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Moderate CYP3A Inhibitors:</span> Verapamil and diltiazem (moderate CYP3A inhibitors) are predicted to increase the relative potency adjusted unbound AUC of abemaciclib plus its active metabolites (M2, M18, and M20) by approximately 1.6-fold and 2.4-fold, respectively.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s82\\\"></a><a name=\\\"section-10.3.5.1.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Strong CYP3A Inducers:</span> Coadministration of 600 mg daily doses of rifampin (a strong CYP3A inducer) with a single 200 mg dose of VERZENIO decreased the relative potency adjusted unbound AUC<span class=\\\"Sub\\\">0-INF</span> of abemaciclib plus its active metabolites (M2, M18, and M20) by approximately 70% in healthy subjects.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s83\\\"></a><a name=\\\"section-10.3.5.1.4\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Moderate CYP3A Inducers:</span> Efavirenz, bosentan, and modafinil (moderate CYP3A inducers) are predicted to decrease the relative potency adjusted unbound AUC of abemaciclib plus its active metabolites (M2, M18, and M20) by 53%, 41%, and 29%, respectively.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s84\\\"></a><a name=\\\"section-10.3.5.1.5\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Loperamide:</span> Co-administration of a single 8 mg dose of loperamide with a single 400 mg dose of abemaciclib in healthy subjects increased the relative potency adjusted unbound AUC<span class=\\\"Sub\\\">0-INF</span> of abemaciclib plus its active metabolites (M2 and M20) by 12%, which is not considered clinically relevant.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s85\\\"></a><a name=\\\"section-10.3.5.1.6\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Endocrine Therapies:</span> In clinical studies in patients with breast cancer, there was no clinically relevant effect of fulvestrant, anastrozole, letrozole, exemestane, or tamoxifen on abemaciclib pharmacokinetics.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s86\\\"></a><a name=\\\"section-10.3.5.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Effects of Abemaciclib on Other Drugs</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s87\\\"></a><a name=\\\"section-10.3.5.2.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Loperamide:</span> In a clinical drug interaction study in healthy subjects, coadministration of a single 8 mg dose of loperamide with a single 400 mg abemaciclib (2.7 times the approved recommended 150 mg dosage) increased loperamide AUC<span class=\\\"Sub\\\">0-INF</span> by 9% and C<span class=\\\"Sub\\\">max</span> by 35% relative to loperamide alone. These increases in loperamide exposure are not considered clinically relevant.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s88\\\"></a><a name=\\\"section-10.3.5.2.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Metformin:</span> In a clinical drug interaction study in healthy subjects, coadministration of a single 1000 mg dose of metformin, a clinically relevant substrate of renal OCT2, MATE1, and MATE2-K transporters, with a single 400 mg dose of abemaciclib (2.7 times the approved recommended 150 mg dosage) increased metformin AUC<span class=\\\"Sub\\\">0-INF</span> by 37% and C<span class=\\\"Sub\\\">max</span> by 22% relative to metformin alone. Abemaciclib reduced the renal clearance and renal secretion of metformin by 45% and 62%, respectively, relative to metformin alone, without any effect on glomerular filtration rate (GFR) as measured by iohexol clearance and serum cystatin C.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s89\\\"></a><a name=\\\"section-10.3.5.2.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Endocrine Therapies:</span> In clinical studies in patients with breast cancer, there was no clinically relevant effect of abemaciclib on the pharmacokinetics of fulvestrant, anastrozole, letrozole, exemestane, or tamoxifen.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s90\\\"></a><a name=\\\"section-10.3.5.2.4\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">CYP Metabolic Pathways:</span> In a clinical drug interaction study in patients with cancer, multiple doses of abemaciclib (200 mg twice daily for 7 days) did not result in clinically meaningful changes in the pharmacokinetics of CYP1A2, CYP2C9, CYP2D6 and CYP3A4 substrates. Abemaciclib is a substrate of CYP3A4, and time-dependent changes in pharmacokinetics of abemaciclib as a result of autoinhibition of its metabolism were not observed.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s91\\\"></a><a name=\\\"section-10.3.5.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">In Vitro Studies</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s92\\\"></a><a name=\\\"section-10.3.5.3.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics Underline\\\">Transporter Systems:</span> Abemaciclib and its major active metabolites inhibit the renal transporters OCT2, MATE1, and MATE2-K at concentrations achievable at the approved recommended dosage. The observed serum creatinine increase in clinical studies with abemaciclib is likely due to inhibition of tubular secretion of creatinine via OCT2, MATE1, and MATE2-K <span class=\\\"Italics\\\">[see Adverse Effects (<a href=\\\"#s23\\\">6.1</a>)]</span>. Abemaciclib and its major metabolites at clinically relevant concentrations do not inhibit the hepatic uptake transporters OCT1, OATP1B1, and OATP1B3 or the renal uptake transporters OAT1 and OAT3.</p><p>Abemaciclib is a substrate of P-gp and BCRP. Abemaciclib and its major active metabolites, M2 and M20, are not substrates of hepatic uptake transporters OCT1, organic anion transporting polypeptide 1B1 (OATP1B1), or OATP1B3.</p><p>Abemaciclib inhibits P-gp and BCRP. The clinical consequences of this finding on sensitive P-gp and BCRP substrates are unknown.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s93\\\"></a><a name=\\\"section-10.3.5.3.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics Underline\\\">P-gp and BCRP Inhibitors:</span> In vitro, abemaciclib is a substrate of P-gp and BCRP. The effect of P-gp or BCRP inhibitors on the pharmacokinetics of abemaciclib has not been studied.</p></div></div></div></div></section>\",\n            \"clinicalStudies\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34092-7\\\"><a name=\\\"s97\\\"></a><a name=\\\"section-12\\\"></a><p></p><h1>14 CLINICAL STUDIES</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s98\\\"></a><a name=\\\"section-12.1\\\"></a><p></p><h2>14.1 Early Breast Cancer</h2><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s99\\\"></a><a name=\\\"section-12.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">VERZENIO in Combination with Standard Endocrine Therapy (monarchE)</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s100\\\"></a><a name=\\\"section-12.1.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence</span></p><p>monarchE (NCT03155997) was a randomized (1:1), open-label, two cohort, multicenter study in adult women and men with HR-positive, HER2-negative, node-positive, resected, early breast cancer with clinical and pathological features consistent with a high risk of disease recurrence. To be enrolled, patients had to have HR-positive HER2-negative early breast cancer with tumor involvement in at least 1 axillary lymph node (pALN) and to be enrolled in cohort 1 had to have either:</p><ul class=\\\"Disc\\\"><li>≥4 pALN or</li><li>1-3 pALN and at least one of:<dl class=\\\"Disc\\\"><dt>–</dt><dd>tumor grade 3 or</dd><dt>–</dt><dd>tumor size ≥50 mm</dd></dl></li></ul><p>Patients enrolled in cohort 2 could not have met the eligibility criteria for cohort 1. To be enrolled in cohort 2, patients had to have 1-3 pALN and Ki-67 score ≥20%. Breast tumor samples were tested at central sites using the Ki-67 IHC MIB-1 pharmDx (Dako Omnis) assay to establish if the Ki-67 score was ≥20%.</p><p>Patients were randomized to receive 2 years of VERZENIO plus physician's choice of standard endocrine therapy or standard endocrine therapy alone. Randomization to treatment was stratified by prior treatment (neoadjuvant chemotherapy versus adjuvant chemotherapy versus no chemotherapy); menopausal status (premenopausal versus postmenopausal); and region (North America/Europe versus Asia versus other). Men were stratified as postmenopausal. After the end of the study treatment period, standard adjuvant endocrine therapy was continued for a duration of at least 5 years if deemed medically appropriate.</p><p>The major efficacy outcome measure was invasive disease–free survival (IDFS). IDFS was defined as the time from randomization to the first occurrence of: ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer, or death attributable to any cause. Overall survival (OS) was an additional outcome measure.</p><p>A statistically significant difference in IDFS was observed in the intent-to-treat (ITT) population which was primarily attributed to the patients treated in cohort 1. While the OS data in cohort 2 remains immature, more deaths were observed among those receiving VERZENIO plus standard endocrine therapy compared to those receiving standard endocrine therapy alone (10/253 vs. 5/264).</p><p>Of 5637 patients randomized, 5120 (91%) were randomized in cohort 1. Patient median age was 51 years (range, 22-89 years), 99% were women, 70% were White, 24% were Asian, 1.7% were Black or African American, 2.1% were American Indian or Alaska Native, and 0.1% were Native Hawaiian or Other Pacific Islander. Forty-three percent of patients were premenopausal. Most patients received prior chemotherapy (37% neoadjuvant, 59% adjuvant) and prior radiotherapy (96%). Sixty-five percent of the patients had 4 or more positive lymph nodes with 22% having ≥10 positive lymph nodes, 41% had Grade 3 tumor, and 24% had pathological tumor size ≥50 mm. The majority of patients (99%) had estrogen receptor positive disease and 87% had progesterone receptor positive disease. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).</p><p>Efficacy results for cohort 1 are summarized in <a href=\\\"#t16\\\">Table 16</a> and <a href=\\\"#fig1\\\">Figure 1</a>. At the time of OS interim analysis 2, OS was immature and a total of 315 (6%) of patients had died in cohort 1.</p><a name=\\\"t16\\\"></a><table width=\\\"100%\\\"><caption><span>Table 16: Efficacy Results in monarchE in Cohort 1</span></caption><col align=\\\"left\\\" width=\\\"46.633%\\\"/><col align=\\\"left\\\" width=\\\"27.500%\\\"/><col align=\\\"left\\\" width=\\\"25.867%\\\"/><tfoot><tr class=\\\"First Last\\\"><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">Abbreviation: CI = confidence interval.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"middle\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">VERZENIO Plus</span><br/><span class=\\\"Bold\\\">Tamoxifen or an Aromatase Inhibitor</span><br/><span class=\\\"Bold\\\">N=2555</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">Tamoxifen or an Aromatase Inhibitor</span><br/><span class=\\\"Bold\\\">N=2565</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"3\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Invasive Disease–Free Survival (IDFS)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Number of patients with an event, n (%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">317 (12)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">474 (18)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Hazard ratio (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" colspan=\\\"2\\\" valign=\\\"top\\\"> 0.65 (0.57, 0.75)</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">IDFS at 48 months, % (95% CI)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">85.5 (83.8, 87.0)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">78.6 (76.7, 80.4)</td></tr></tbody></table><p class=\\\"MultiMediaCaption\\\"><a name=\\\"fig1\\\"></a><span class=\\\"Bold\\\">Figure 1: Kaplan-Meier Curves of Invasive Disease–Free Survival VERZENIO plus Tamoxifen or an Aromatase Inhibitor versus Tamoxifen or an Aromatase Inhibitor in Cohort 1 (monarchE)</span></p><div class=\\\"Figure\\\"><a name=\\\"f02\\\"></a><img alt=\\\"Figure 1\\n\\\" src=\\\"verzenio-pi-f1-v5.jpg\\\"/></div></div></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s101\\\"></a><a name=\\\"section-12.2\\\"></a><p></p><h2>14.2 Advanced or Metastatic Breast Cancer</h2><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s102\\\"></a><a name=\\\"section-12.2.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">VERZENIO in Combination with an Aromatase Inhibitor (Anastrozole or Letrozole) (MONARCH 3)</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s103\\\"></a><a name=\\\"section-12.2.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer with no prior systemic therapy in this disease setting</span></p><p>MONARCH 3 (NCT02246621) was a randomized (2:1), double-blinded, placebo-controlled, multicenter study in postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with a nonsteroidal aromatase inhibitor as initial endocrine-based therapy, including patients not previously treated with systemic therapy for breast cancer.</p><p>Randomization was stratified by disease site (visceral, bone only, or other) and by prior (neo)adjuvant endocrine therapy (aromatase inhibitor versus other versus no prior endocrine therapy). A total of 493 patients were randomized to receive 150 mg VERZENIO or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20% of patients). Patient median age was 63 years (range, 32-88 years) and the majority were White (58%) or Asian (30%). A total of 51% had received prior systemic therapy and 39% of patients had received chemotherapy, 53% had visceral disease, and 22% had bone-only disease.</p><p>Efficacy results are summarized in <a href=\\\"#t17\\\">Table 17</a> and <a href=\\\"#fig2\\\">Figure 2</a>. PFS was evaluated according to RECIST version 1.1 and PFS assessment based on a blinded independent radiologic review was consistent with the investigator assessment. Consistent PFS results were observed across patient stratification subgroups of disease site and prior (neo)adjuvant endocrine therapy. </p><a name=\\\"t17\\\"></a><table width=\\\"100%\\\"><caption><span>Table 17: Efficacy Results in MONARCH 3 (Investigator Assessment, Intent-to-Treat Population)</span></caption><col align=\\\"left\\\" width=\\\"43.785%\\\"/><col align=\\\"left\\\" width=\\\"28.790%\\\"/><col align=\\\"left\\\" width=\\\"27.424%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">Abbreviations: CI = confidence interval; OS = overall survival; NR = not reached; NS = not statistically significant.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Complete response + partial response.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Based upon confirmed responses.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"middle\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">VERZENIO plus</span><br/><span class=\\\"Bold\\\">Anastrozole or Letrozole</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo plus</span><br/><span class=\\\"Bold\\\">Anastrozole or Letrozole</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Progression-Free Survival</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">N=328</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">N=165</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Number of patients with an event, n (%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">138 (42)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">108 (65)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Median in months (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">28.2 (23.5, NR)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">14.8 (11.2, 19.2)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Hazard ratio (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" colspan=\\\"2\\\" valign=\\\"top\\\">0.54 (0.42, 0.70)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     p-value</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" colspan=\\\"2\\\" valign=\\\"top\\\">&lt;0.0001</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Overall Survival</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">N=328</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">N=165</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Number of patients with an event, n (%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">198 (60)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">116 (70)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Median in months (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">66.8 (59.2, 74.8)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">53.7 (44.7, 59.3)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Hazard ratio (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" colspan=\\\"2\\\" valign=\\\"top\\\">0.80 (0.64, 1.02)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     p-value</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" colspan=\\\"2\\\" valign=\\\"top\\\"> NS</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Objective Response for Patients with Measurable Disease<span class=\\\"Sup\\\">a</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">N=267</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">N=132</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Objective response rate n (%)<span class=\\\"Sup\\\">a,b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">148 (55)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">53 (40)</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     95% CI</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">49, 61</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">32, 49</td></tr></tbody></table><p class=\\\"MultiMediaCaption\\\"><a name=\\\"fig2\\\"></a><span class=\\\"Bold\\\">Figure 2: Kaplan-Meier Curves of Progression-Free Survival: VERZENIO plus Anastrozole or Letrozole versus Placebo plus Anastrozole or Letrozole in Intent-to-Treat Population (MONARCH 3)</span></p><div class=\\\"Figure\\\"><a name=\\\"f03\\\"></a><img alt=\\\"Figure 2\\n\\\" src=\\\"verzenio-pi-f2-v3.jpg\\\"/></div></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s104\\\"></a><a name=\\\"section-12.2.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">VERZENIO in Combination with Fulvestrant (MONARCH 2)</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s105\\\"></a><a name=\\\"section-12.2.2.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression on or after prior adjuvant or metastatic endocrine therapy</span></p><p>MONARCH 2 (NCT02107703) was a randomized, placebo-controlled, multicenter study in women with HR-positive, HER2-negative metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy who had not received chemotherapy in the metastatic setting. Randomization was stratified by disease site (visceral, bone only, or other) and by sensitivity to prior endocrine therapy (primary or secondary resistance). Primary endocrine therapy resistance was defined as relapse while on the first 2 years of adjuvant endocrine therapy or progressive disease within the first 6 months of first line endocrine therapy for metastatic breast cancer. A total of 669 patients were randomized to receive VERZENIO or placebo orally twice daily plus intramuscular injection of 500 mg fulvestrant on days 1 and 15 of cycle 1 and then on day 1 of cycle 2 and beyond (28-day cycles). Pre/perimenopausal women were enrolled in the study and received the gonadotropin-releasing hormone agonist goserelin for at least 4 weeks prior to and for the duration of MONARCH 2. Patients remained on continuous treatment until development of progressive disease or unmanageable toxicity.</p><p>Patient median age was 60 years (range, 32-91 years), and 37% of patients were older than 65. The majority were White (56%), and 99% of patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Twenty percent (20%) of patients had de novo metastatic disease, 27% had bone-only disease, and 56% had visceral disease. Twenty-five percent (25%) of patients had primary endocrine therapy resistance. Seventeen percent (17%) of patients were pre- or perimenopausal.</p><p>The efficacy results from the MONARCH 2 study are summarized in <a href=\\\"#t18\\\">Table 18</a>, <a href=\\\"#fig3\\\">Figure 3</a>, and <a href=\\\"#fig4\\\">Figure 4</a>. PFS assessment based on a blinded independent radiologic review was consistent with the investigator assessment. Consistent results were observed across patient stratification subgroups of disease site and endocrine therapy resistance for PFS and OS.</p><a name=\\\"t18\\\"></a><table width=\\\"100%\\\"><caption><span>Table 18: Efficacy Results in MONARCH 2 (Intent-to-Treat Population)</span></caption><col align=\\\"left\\\" width=\\\"43.785%\\\"/><col align=\\\"left\\\" width=\\\"28.790%\\\"/><col align=\\\"left\\\" width=\\\"27.424%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">Abbreviation: CI = confidence interval, OS = overall survival.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Stratified by disease site (visceral metastases vs. bone-only metastases vs. other) and endocrine therapy resistance (primary resistance vs. secondary resistance)</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Data from a pre-specified interim analysis (77% of the number of events needed for the planned final analysis) with the p-value compared with the allocated alpha of 0.021.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> Complete response + partial response.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"middle\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">VERZENIO plus Fulvestrant</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo plus Fulvestrant</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Progression-Free Survival</span><br/><span class=\\\"Bold\\\">(Investigator Assessment)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">N=446</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">N=223</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Number of patients with an event n (%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">222 (50)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">157 (70)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Median in months (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">16.4 (14.4, 19.3)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">9.3 (7.4, 12.7)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Hazard ratio (95% CI)<span class=\\\"Sup\\\">a</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" colspan=\\\"2\\\" valign=\\\"top\\\">0.55 (0.45, 0.68)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     p-value<span class=\\\"Sup\\\">a</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" colspan=\\\"2\\\" valign=\\\"top\\\">p&lt;.0001</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"3\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Overall Survival</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">b</span></span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Number of deaths n (%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">211 (47)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">127 (57)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Median OS in months (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">46.7 (39.2, 52.2)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">37.3 (34.4, 43.2)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Hazard ratio (95% CI)<span class=\\\"Sup\\\">a</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" colspan=\\\"2\\\" valign=\\\"top\\\">0.76 (0.61, 0.95)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     p-value<span class=\\\"Sup\\\">a</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" colspan=\\\"2\\\" valign=\\\"top\\\">p=.0137</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Objective Response for Patients with Measurable Disease</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">N=318</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">N=164</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Objective response rate n (%)<span class=\\\"Sup\\\">c</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">153 (48)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">35 (21)</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     95% CI</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">43, 54</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">15, 28</td></tr></tbody></table><p class=\\\"MultiMediaCaption\\\"><a name=\\\"fig3\\\"></a><span class=\\\"Bold\\\">Figure 3: Kaplan-Meier Curves of Progression-Free Survival: VERZENIO plus Fulvestrant versus Placebo plus Fulvestrant (MONARCH 2)</span></p><div class=\\\"Figure\\\"><a name=\\\"f04\\\"></a><img alt=\\\"Figure 3\\n\\\" src=\\\"verzenio-pi-f3-v2.jpg\\\"/></div><p class=\\\"MultiMediaCaption\\\"><a name=\\\"fig4\\\"></a><span class=\\\"Bold\\\">Figure 4: Kaplan-Meier Curves of Overall Survival: VERZENIO plus Fulvestrant versus Placebo plus Fulvestrant (MONARCH 2)</span></p><div class=\\\"Figure\\\"><a name=\\\"f05\\\"></a><img alt=\\\"Figure 4\\n\\\" src=\\\"verzenio-pi-f4-v2.jpg\\\"/></div></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s106\\\"></a><a name=\\\"section-12.2.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">VERZENIO Administered as a Monotherapy in Metastatic Breast Cancer (MONARCH 1)</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s107\\\"></a><a name=\\\"section-12.2.3.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Patients with HR-positive, HER2-negative breast cancer who received prior endocrine therapy and 1-2 chemotherapy regimens in the metastatic setting</span></p><p>MONARCH 1 (NCT02102490) was a single-arm, open-label, multicenter study in women with measurable HR-positive, HER2-negative metastatic breast cancer whose disease progressed during or after endocrine therapy, had received a taxane in any setting, and who received 1 or 2 prior chemotherapy regimens in the metastatic setting. A total of 132 patients received 200 mg VERZENIO orally twice daily on a continuous schedule until development of progressive disease or unmanageable toxicity.</p><p>Patient median age was 58 years (range, 36-89 years), and the majority of patients were White (85%). Patients had an Eastern Cooperative Oncology Group performance status of 0 (55% of patients) or 1 (45%). The median duration of metastatic disease was 27.6 months. Ninety percent (90%) of patients had visceral metastases, and 51% of patients had 3 or more sites of metastatic disease. Fifty-one percent (51%) of patients had had one line of chemotherapy in the metastatic setting. Sixty-nine percent (69%) of patients had received a taxane-based regimen in the metastatic setting and 55% had received capecitabine in the metastatic setting. <a href=\\\"#t19\\\">Table 19</a> provides the efficacy results from MONARCH 1.</p><a name=\\\"t19\\\"></a><table width=\\\"100%\\\"><caption><span>Table 19: Efficacy Results in MONARCH 1 (Intent-to-Treat Population)</span></caption><col align=\\\"left\\\" width=\\\"54.667%\\\"/><col align=\\\"left\\\" width=\\\"22.667%\\\"/><col align=\\\"left\\\" width=\\\"22.667%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">Abbreviations: CI = confidence interval, NR = not reached.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> All responses were partial responses.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Based upon confirmed responses.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"middle\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">VERZENIO 200 mg</span><br/><span class=\\\"Bold\\\">N=132</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Investigator Assessed</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Independent Review</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Objective Response Rate</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">a,b</span></span><span class=\\\"Bold\\\">, n (%)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">26 (20)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">23 (17)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">95% CI</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">13, 28</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">11, 25</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Median Duration of Response in months</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.2</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">95% CI </td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">5.8, 10.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">5.6, NR</td></tr></tbody></table></div></div></div></section>\",\n            \"howSupplied\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34069-5\\\"><a name=\\\"s109\\\"></a><a name=\\\"section-13.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">How Supplied</span></p><p>VERZENIO 50 mg tablets are oval beige tablet with “Lilly” debossed on one side and “50” on the other side.</p><p>VERZENIO 100 mg tablet are oval white to practically white tablet with “Lilly” debossed on one side and “100” on the other side.</p><p>VERZENIO 150 mg tablets are oval yellow tablet with “Lilly” debossed on one side and “150” on the other side.</p><p>VERZENIO 200 mg tablets are oval beige tablet with “Lilly” debossed on one side and “200” on the other side.</p><p>VERZENIO tablets are supplied in 7-day dose pack configurations as follows:</p><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"100.000%\\\"/><tbody class=\\\"Headless\\\"><tr><td align=\\\"left\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>200 mg dose pack (14 tablets) – each blister pack contains 14 tablets (200 mg per tablet) (200 mg twice daily)</li></ul></td></tr><tr><td align=\\\"right\\\" valign=\\\"top\\\">NDC 0002-6216-54</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>150 mg dose pack (14 tablets) – each blister pack contains 14 tablets (150 mg per tablet) (150 mg twice daily)</li></ul></td></tr><tr><td align=\\\"right\\\" valign=\\\"top\\\">NDC 0002-5337-54</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>100 mg dose pack (14 tablets) – each blister pack contains 14 tablets (100 mg per tablet) (100 mg twice daily)</li></ul></td></tr><tr><td align=\\\"right\\\" valign=\\\"top\\\">NDC 0002-4815-54</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>50 mg dose pack (14 tablets) – each blister pack contains 14 tablets (50 mg per tablet) (50 mg twice daily)</li></ul></td></tr><tr><td align=\\\"right\\\" valign=\\\"top\\\">NDC 0002-4483-54</td></tr></tbody></table></section>\",\n            \"useInSpecificPopulations\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43684-0\\\"><a name=\\\"s45\\\"></a><a name=\\\"section-8\\\"></a><p></p><h1>8 USE IN SPECIFIC POPULATIONS</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42228-7\\\"><a name=\\\"s46\\\"></a><a name=\\\"section-8.1\\\"></a><p></p><h2>8.1 Pregnancy</h2><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s47\\\"></a><a name=\\\"section-8.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Risk Summary</span></p><p>Based on findings in animals and its mechanism of action, VERZENIO can cause fetal harm when administered to a pregnant woman <span class=\\\"Italics\\\">[see Clinical Pharmacology (<a href=\\\"#s64\\\">12.1</a>)]</span>. There are no available human data informing the drug-associated risk. Advise pregnant women of the potential risk to a fetus. In animal reproduction studies, administration of abemaciclib during organogenesis was teratogenic and caused decreased fetal weight at maternal exposures that were similar to human clinical exposure based on AUC at the maximum recommended human dose (<span class=\\\"Italics\\\">see</span> Data). Advise pregnant women of the potential risk to a fetus.</p><p>The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s48\\\"></a><a name=\\\"section-8.1.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Data</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s49\\\"></a><a name=\\\"section-8.1.2.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Animal Data</span></p><p>In an embryo-fetal development study, pregnant rats received oral doses of abemaciclib up to 15 mg/kg/day during the period of organogenesis. Doses ≥4 mg/kg/day caused decreased fetal body weights and increased incidence of cardiovascular and skeletal malformations and variations. These findings included absent innominate artery and aortic arch, malpositioned subclavian artery, unossified sternebra, bipartite ossification of thoracic centrum, and rudimentary or nodulated ribs. At 4 mg/kg/day in rats, the maternal systemic exposures were approximately equal to the human exposure (AUC) at the recommended dose.</p></div></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"77290-5\\\"><a name=\\\"s50\\\"></a><a name=\\\"section-8.2\\\"></a><p></p><h2>8.2 Lactation</h2><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s51\\\"></a><a name=\\\"section-8.2.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Risk Summary</span></p><p>There are no data on the presence of abemaciclib in human milk, or its effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed infants from VERZENIO, advise lactating women not to breastfeed during VERZENIO treatment and for 3 weeks after the last dose.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"77291-3\\\"><a name=\\\"s52\\\"></a><a name=\\\"section-8.3\\\"></a><p></p><h2>8.3 Females and Males of Reproductive Potential</h2><p class=\\\"First\\\">Based on animal studies, VERZENIO can cause fetal harm when administered to a pregnant woman <span class=\\\"Italics\\\">[see Use in Specific Populations (<a href=\\\"#s46\\\">8.1</a>)]</span>.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s53\\\"></a><a name=\\\"section-8.3.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Pregnancy Testing</span></p><p>Verify pregnancy status in females of reproductive potential prior to initiating treatment with VERZENIO.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s54\\\"></a><a name=\\\"section-8.3.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Contraception</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s55\\\"></a><a name=\\\"section-8.3.2.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Females</span></p><p>Advise females of reproductive potential to use effective contraception during VERZENIO treatment and for 3 weeks after the last dose.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s56\\\"></a><a name=\\\"section-8.3.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Infertility</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s57\\\"></a><a name=\\\"section-8.3.3.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Males</span></p><p>Based on findings in animals, VERZENIO may impair fertility in males of reproductive potential <span class=\\\"Italics\\\">[see Nonclinical Toxicology (<a href=\\\"#s95\\\">13.1</a>)]</span>.</p></div></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"34081-0\\\"><a name=\\\"s58\\\"></a><a name=\\\"section-8.4\\\"></a><p></p><h2>8.4 Pediatric Use</h2><p class=\\\"First\\\">The safety and effectiveness of VERZENIO have not been established in pediatric patients.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"34082-8\\\"><a name=\\\"s59\\\"></a><a name=\\\"section-8.5\\\"></a><p></p><h2>8.5 Geriatric Use</h2><p class=\\\"First\\\">Of the 2791 VERZENIO-treated patients in monarchE, 15% were 65 years of age or older and 2.7% were 75 years of age or older.</p><p>Of the 900 patients who received VERZENIO in MONARCH 1, MONARCH 2, and MONARCH 3, 38% were 65 years of age or older and 10% were 75 years of age or older. The most common adverse reactions (≥5%) Grade 3 or 4 in patients ≥65 years of age across MONARCH 1, 2, and 3 were: neutropenia, diarrhea, fatigue, nausea, dehydration, leukopenia, anemia, infections, and ALT increased.</p><p>No overall differences in safety or effectiveness of VERZENIO were observed between these patients and younger patients.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"88828-9\\\"><a name=\\\"s60\\\"></a><a name=\\\"section-8.6\\\"></a><p></p><h2>8.6 Renal Impairment</h2><p class=\\\"First\\\">No dosage adjustment is required for patients with mild or moderate renal impairment (CLcr ≥30-89 mL/min, estimated by Cockcroft-Gault [C-G]). The pharmacokinetics of abemaciclib in patients with severe renal impairment (CLcr &lt;30 mL/min, C-G), end stage renal disease, or in patients on dialysis is unknown <span class=\\\"Italics\\\">[see Clinical Pharmacology (<a href=\\\"#s67\\\">12.3</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"88829-7\\\"><a name=\\\"s61\\\"></a><a name=\\\"section-8.7\\\"></a><p></p><h2>8.7 Hepatic Impairment</h2><p class=\\\"First\\\">No dosage adjustments are necessary in patients with mild or moderate hepatic impairment (Child-Pugh A or B).</p><p>Reduce the dosing frequency when administering VERZENIO to patients with severe hepatic impairment (Child-Pugh C) <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s9\\\">2.2</a>) and Clinical Pharmacology (<a href=\\\"#s67\\\">12.3</a>)]</span>.</p></div></section>\",\n            \"description\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34089-3\\\"><a name=\\\"s62\\\"></a><a name=\\\"section-9\\\"></a><p></p><h1>11 DESCRIPTION</h1><p class=\\\"First\\\">Abemaciclib is a kinase inhibitor for oral administration. It is a white to yellow powder with the empirical formula C<span class=\\\"Sub\\\">27</span>H<span class=\\\"Sub\\\">32</span>F<span class=\\\"Sub\\\">2</span>N<span class=\\\"Sub\\\">8</span> and a molecular weight 506.59.</p><p>The chemical name for abemaciclib is 2-Pyrimidinamine, <span class=\\\"Italics\\\">N</span>-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1<span class=\\\"Italics\\\">H</span>-benzimidazol-6-yl]-. Abemaciclib has the following structure:</p><div class=\\\"Figure\\\"><a name=\\\"f01\\\"></a><img alt=\\\"Abemaciclib Structure\\n\\\" src=\\\"verzenio-pi-chem-struct-v2.jpg\\\"/></div><p>VERZENIO (abemaciclib) tablets are provided as immediate-release oval white, beige, or yellow tablets. Inactive ingredients are as follows: Excipients—microcrystalline cellulose 102, microcrystalline cellulose 101, lactose monohydrate, croscarmellose sodium, sodium stearyl fumarate, silicon dioxide. Color mixture ingredients—polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide yellow, and iron oxide red.</p></section>\",\n            \"nonclinicalToxicology\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43680-8\\\"><a name=\\\"s94\\\"></a><a name=\\\"section-11\\\"></a><p></p><h1>13 NONCLINICAL TOXICOLOGY</h1><div class=\\\"Section\\\" data-sectioncode=\\\"34083-6\\\"><a name=\\\"s95\\\"></a><a name=\\\"section-11.1\\\"></a><p></p><h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2><p class=\\\"First\\\">Abemaciclib was assessed for carcinogenicity in a 2-year rat study. Abemaciclib was not carcinogenic in male and female rats at oral doses up to 3 mg/kg/day (approximately 1 time the exposure at the maximum recommended human dose based on AUC).</p><p>Abemaciclib and its active human metabolites M2 and M20 were not mutagenic in a bacterial reverse mutation (Ames) assay or clastogenic in an in vitro chromosomal aberration assay in Chinese hamster ovary cells or human peripheral blood lymphocytes. Abemaciclib, M2, and M20 were not clastogenic in an in vivo rat bone marrow micronucleus assay.</p><p>Abemaciclib may impair fertility in males of reproductive potential. In repeat-dose toxicity studies up to 3-months duration, abemaciclib-related findings in the testis, epididymis, prostate, and seminal vesicle at doses ≥10 mg/kg/day in rats and ≥0.3 mg/kg/day in dogs included decreased organ weights, intratubular cellular debris, hypospermia, tubular dilatation, atrophy, and degeneration/necrosis. These doses in rats and dogs resulted in approximately 2 and 0.02 times, respectively, the exposure (AUC) in humans at the maximum recommended human dose. In a rat male fertility study, abemaciclib had no effects on mating and fertility at oral doses up to 10 mg/kg/day (approximately 2 times the exposure at the maximum recommended human dose based on AUC).</p><p>In a rat female fertility and early embryonic development study, abemaciclib did not affect mating and fertility at doses up to 20 mg/kg/day (approximately 3 times the exposure at the maximum recommended human dose based on AUC).</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"34091-9\\\"><a name=\\\"s96\\\"></a><a name=\\\"section-11.2\\\"></a><p></p><h2>13.2 Animal Toxicology and/or Pharmacology</h2><p class=\\\"First\\\">In repeat-dose toxicity studies up to 6-months duration, oral administration of abemaciclib resulted in retinal atrophy of the eyes in mice at a dose of 150 mg/kg/day (approximately 10 times the exposure at the maximum recommended human dose based on AUC) and in rats at a dose of 30 mg/kg/day (approximately 5 times the exposure at the maximum recommended human dose based on AUC). In a 2-year rat carcinogenicity study, oral administration of abemaciclib resulted in retinal atrophy in the eyes at doses ≥0.3 mg/kg/day (approximately 0.05 times the exposure at the maximum recommended human dose based on AUC).</p></div></section>\",\n            \"mechanismOfAction\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43679-0\\\"><a name=\\\"s64\\\"></a><a name=\\\"section-10.1\\\"></a><p></p><h2>12.1 Mechanism of Action</h2><p class=\\\"First\\\">Abemaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). These kinases are activated upon binding to D-cyclins. In estrogen receptor-positive (ER+) breast cancer cell lines, cyclin D1 and CDK4/6 promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation. In vitro, continuous exposure to abemaciclib inhibited Rb phosphorylation and blocked progression from G1 into S phase of the cell cycle, resulting in senescence and apoptosis. In breast cancer xenograft models, abemaciclib dosed daily without interruption as a single agent or in combination with antiestrogens resulted in reduction of tumor size.</p></section>\",\n            \"contraindications\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34070-3\\\"><a name=\\\"s14\\\"></a><a name=\\\"section-4\\\"></a><p></p><h1>4 CONTRAINDICATIONS</h1><p class=\\\"First\\\">None.</p></section>\",\n            \"highlights\": {\n                \"dosageAndAdministration\": \"<div><p class=\\\"Highlighta\\\">VERZENIO tablets are taken orally with or without food. (<a href=\\\"#s8\\\">2.1</a>) </p><ul class=\\\"Disc\\\"><li>Recommended starting dose in combination with fulvestrant, tamoxifen, or an aromatase inhibitor: 150 mg twice daily. (<a href=\\\"#s8\\\">2.1</a>)</li><li>Recommended starting dose as monotherapy: 200 mg twice daily. (<a href=\\\"#s8\\\">2.1</a>)</li><li>Dosing interruption and/or dose reductions may be required based on individual safety and tolerability. (<a href=\\\"#s9\\\">2.2</a>)</li></ul></div>\"\n            }\n        }\n    }\n]"